Donate
info@cureduchenne.org(949) 872-2552
EventsContact
Cart
×

No products in the cart.

CureDuchenne
Moble Nav Icon
  • Cure
    • Research Overview
    • Research Terms
    • Exon Skipping
    • Clinical Trials
  • Care
    • COVID-19 Resources
    • Newly Diagnosed
    • Clinics
    • Steroid Use
    • Emergency Care
    • Resource Library
    • DME Guide
    • Medical ID Bracelets
    • Navigating School
    • Occupational Therapy
    • Physical Therapy
    • For Families
    • - Find a Physical Therapist
    • - Pool Activities
    • - Stretching
    • For Physical Therapists
    • - PT Certification
    • - Professional Courses
    • For Clinics
  • Community
    • CureDuchenne CARES
    • CureDuchenne FUTURES
    • CureDuchenne Champions
    • Family Stories
    • Events
    • Previous Webinars
    • Family Fundraisers
  • About Us
    • Mission
    • Vision
    • About Duchenne
    • Blog
    • Board of Directors
    • Sponsors
    • Reports and Financials
    • Events & Webinars
    • News Center
    • - Press Releases
    • - Research
  • CD Ventures
    • About CD Ventures
    • Our Impact
  • Get Involved
    • Donate
    • More Ways to Give
    • Fundraise
    • Shop
    • Fundraising Events
    • - Ladies Luncheon Austin
    • - CureDuchenne Golf Shootout | Orange County, CA
    • - Napa in Newport | Orange County, CA
  • Donate

Between the Vines

Related Posts

  • Nonviral Gene Therapy
    CureDuchenne Invests in SonoThera to Advance Nonviral Gene Therapy Platform for Duchenne Muscular Dystrophy
    June 10, 2026
  • Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027
    June 4, 2026
  • Entrada shares updates on Duchenne programs, including initiation of Cohort 2 in UK and EU trial skipping exon 45
    June 2, 2026
  • Servier’s Acquisition of Edgewise’s Sevasemten Marks Major Milestone for Becker and Duchenne Muscular Dystrophy Communities 
    June 1, 2026

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate

Search

Recent Posts

  • CureDuchenne Invests in SonoThera to Advance Nonviral Gene Therapy Platform for Duchenne Muscular Dystrophy
    June 10, 2026
  • Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027
    June 4, 2026
  • Entrada shares updates on Duchenne programs, including initiation of Cohort 2 in UK and EU trial skipping exon 45
    June 2, 2026
  • Servier’s Acquisition of Edgewise’s Sevasemten Marks Major Milestone for Becker and Duchenne Muscular Dystrophy Communities 
    June 1, 2026
  • Dyne submits Biologics License Application (BLA) to the FDA for Exon 51-skipping z-rostudirsen
    May 26, 2026

Categories

  • Cure Duchenne Blog
  • Press Releases
  • In the News
  • Research Articles

Categories

  • All Categories
  • 2024 FUTURES
  • Clinical Care
  • Community
  • Equipment
  • Financial Assistance
  • Industry Presentations
  • Mental Health
  • Physical Therapy
  • Recursos en español
  • Research and Clinical Trials
  • School
  • About

    • Mission
    • About Duchenne MD
    • Blog
    • Store
    • News Center
  • Get Involved

    • Donate
    • Fundraising
    • Attend an Event
  • CureDuchenne

    • 100 Bayview Circle, Suite 5600
      Newport Beach, CA 92660
      (949) 872-2552
      info@cureduchenne.org

  • Get Connected

PRIVACY POLICY | TERMS OF USE | INDIRECT COST POLICY | TAX INFO

CureDuchenne is a 501c3 registered tax-exempt nonprofit organization. Federal Tax ID: #20-0299958 | ©2026 CureDuchenne. All rights reserved.

Please be advised that the contents within the CureDuchenne site include a compilation of articles, advisements, and references from the community. CureDuchenne does not provide medical advice nor is CureDuchenne a medical provider. The intent of this shared content is to serve as a point of reference for informational purposes. Please refer to your health care provider(s) for your individualized, specific care management needs. The CureDuchenne website may contain links to external websites that are not provided and/or maintained by or in any way affiliated with CureDuchenne. CureDuchenne recommends that you review the terms of service and privacy policies of these external websites before entering. Please note that CureDuchenne does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree